Josh Hexter, Oramed's COO, spoke with BioTuesdays.com about Oramed's progress and future advances. "Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and [...]
seekingalpha.com/article/3723676-50-million-plus-royalties-deal-indicates-bright-future-for-orameds-oral-insulin?app=1&auth_param=k8111%3A1b5r8j9%3A005181aa590ef2f22df1979bdbb995c2&uprof=78
www.in-pharmatechnologist.com/Drug-Delivery/Oramed-inks-China-licensing-deal-for-oral-insulin-candidate
www.timesofisrael.com/oramed-inks-huge-50m-deal-with-chinese-pharma-firm/?utm_source=dlvr.it&utm_medium=twitter
Josh Hexter, Oramed's COO, met with SNNLive at the Aegis Conference in August about Oramed and it's progress http://stocknewsnow.com/commentary/ANEWSID08112015100001/$ORMP-SNNLive-Video-Interview-with-Oramed-Pharmaceuticals
Josh Hexter, Oramed's COO, spoke with BioPharma Dive about Oramed's product and progress. “Our oral insulin is not a substitute for insulin injections, but rather a new, earlier treatment option.” http://www.biopharmadive.com/news/a-21st-century-diabetes-option-will-oramed-be-first-to-market-with-oral-in/402100/
http://seekingalpha.com/instablog/1240561-ray-dirks/4161215-orameds-quick-road-to-market-as-global-leader-of-oral-insulin-capsule
By: Dan Stanton http://www.in-pharmatechnologist.com/Drug-Delivery/Oramed-Desire-for-alternative-insulin-delivery-shown-with-Afrezza
Listen in to find out more about these made-in-Israel technologies aimed at improving quality of life for people with diabetes (audio): http://www.israel21c.org/headlines/tech-firms-target-diabetes-audio/?utm_content=bufferff52d&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer
http://www.reuters.com/video/2014/03/30/reuters-tv-clinical-trials-hold-promise-for-worlds?videoId=300847050&videoChannel=118065